Empirical Versus Pre-emptive (Diagnostic-driven) Antifungal Therapy of Patients Treated for Haematological Malignancies or Receiving an Allogeneic Stem Cell Transplant. A Therapeutic Open Label Phase III Strategy Study of the EORTC Infectious Diseases and Leukemia Groups
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Caspofungin (Primary)
- Indications Mycoses
- Focus Therapeutic Use
- 12 Dec 2017 Planned End Date changed from 1 Jul 2016 to 1 Jul 2018.
- 12 Dec 2017 Planned primary completion date changed from 1 Aug 2015 to 1 Jul 2018.
- 10 Jun 2017 Biomarkers information updated